Patent intelligence · US
US 2012100163
SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN
SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN
Patent details — US 2012100163
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 26, 2012
- Expiration
- Apr 21, 2032
- Applicant
- BRIMNES JENS [DK]
- CPC classes
- A61K 39/ 00 A I, A61K/3935, A61K/3936, A61P 37/ 06 A I
Quick answer
US 2012100163 (SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN) is held by BRIMNES JENS [DK]. Status: granted. Granted Apr 26, 2012. Expires Apr 21, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BRIMNES JENS [DK]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 00 A I, A61K/3935, A61K/3936, A61P 37/ 06 A I, A61P/3700, A61P/3706
More from BRIMNES JENS [DK]
Related pharmaceutical patents in our USPTO index.
-
WO 2024200854
ANTICORPS DE LIAISON AUX ALLERGÈNES APPROPRIÉS POUR TRAITER DES ALLERGIES AU POLLEN D'ARBRE
granted -
EP 4302751
ORALE DÜNNFILME MIT GERINGER WASSERAKTIVITÄT
granted -
EP 4302750
ORALE DÜNNFILME ENTHALTEND ADRENALIN
granted -
CA 3259886
DISPOSITIFS DE DÉPLACEMENT D'IGE-FCERI
granted -
WO 2023232958
INHIBITEURS DE LA KINASE DE BRUTON POUR LE TRAITEMENT D'UNE RÉACTION ALLERGIQUE SOUDAINE
granted -
CA 3255134
COMPOSITION D'ALLERGÈNE D'ARACHIDE
granted -
WO 2019224246
MÉTHODES FONDÉES SUR DES BIOMARQUEURS DESTINÉES AU TRAITEMENT D'UNE MALADIE ATOPIQUE PAR IMMUNOTHÉRAPIE
granted -
HK 1249412
PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF
granted
Frequently asked questions
What is US patent 2012100163?
US 2012100163 (SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN) is held by BRIMNES JENS [DK]. Status: granted. Granted Apr 26, 2012. Expires Apr 21, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2012100163?
BRIMNES JENS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2012100163 expire?
Our index shows an expiration date of Apr 21, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.